Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for ...

The global diabetic macular edema market is on a steady growth trajectory, with an expected valuation of approximately USD 4,120.9 million in 2024. The market is poised to surpass USD 4,642.9 million ...

With an array of new medicines and medical devices on display global medical companies are looking to tap further into the ...

The Indian pharmaceutical market (IPM) registered a 6.1 per cent value growth in October 2024, with major therapies showing ...

Bayer’s BREEZE 2 has a useful on-board disc ... the BREEZE 2 can test with ease and keep better control of diabetes.

With an array of new medicines and medical devices on display, global medical companies are looking to tap further into the ...

"China market is one of the most attractive markets for Edwards," said Leo Tam, senior director of the business unit of Transcatheter Aortic Valve Replacement, Edwards Lifesciences China, citing a lot ...

Patients with diabetes mellitus have a high risk of cardiovascular ... SE Kjeldsen has received honoraria from AstraZeneca, Bayer, Boehringer-Ingelheim, Leo, Medtronic, Nycomed and Takeda, and ...

Bayer has launched a digital patient support package in England designed to help people with type 2 diabetes look after the health of their kidneys and avoid progression to chronic kidney disease ...

Bayer has claimed EU approval for Kerendia, its new drug for chronic kidney disease (CKD) in people with type 2 diabetes, as the company tries to build a role of the drug alongside rival therapies ...

boosted by its cancer and diabetes medicines, and laid out plans for a multibillion-dollar investment in the U.S. Bayer Cuts Earnings Outlook The pharmaceutical-and-agricultural group lowered its ...